Zanubrutinib May Affect the Heart Less Than Ibrutinib and Acalabrutinib in CLL/SLL
Zanubrutinib to treat chronic lymphocytic leukemia or small lymphocytic lymphoma was linked with fewer cardiac adverse effects compared with ibrutinib and acalabrutinib.